ClinicalTrials.gg
Not yet recruitingNCT07934238Updated Nov 12, 2026

Effect of Earmuffs on Physiological Stability, Sleep-Wake States, and Weight Gain in Preterm Neonates

An interventional study of Neonatal Earmuffs in Preterm Infants, sponsored by University of Baghdad. Not yet recruiting at 1 site in Iraq. Open to participants aged 1 Day to 14 Days. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Baghdad · Not applicable, Interventional, and Supportive care

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
1 Day to 14 Days
Sex
All
01

Study summary

This study aims to evaluate the effect of earmuffs on physiological stability, sleep-wake states, and weight gain in preterm neonates admitted to neonatal intensive care units (NICUs). The study will compare preterm neonates receiving earmuffs in addition to routine nursing care with those receiving routine nursing care alone. Physiological stability will be assessed by measuring heart rate, respiratory rate, oxygen saturation, and body temperature. Sleep-wake states will be assessed using the Anderson Behavioral State Scoring (ABSS) system, and weight gain will be evaluated through body-weight measurements. The study may provide evidence on the potential role of earmuffs as a supportive nursing intervention for preterm neonates.

Read the detailed description

Preterm neonates admitted to neonatal intensive care units (NICUs) may be exposed to environmental noise generated by monitoring devices, alarms, respiratory support equipment, and routine staff activities. Because preterm neonates have immature physiological and neurological systems, protecting their developmental environment is an important aspect of neonatal supportive care.

Earmuffs may help reduce neonates' exposure to environmental noise. However, their effects on physiological stability, sleep-wake states, and weight gain need further evaluation. This study will investigate these outcomes to contribute evidence on the potential role of earmuffs in supportive nursing care for preterm neonates.

02

Conditions studied

  • Preterm Infants

Keywords

  • Premature Infants
  • Earmuffs
  • Physiological Stability
  • Sleep-Wake States
  • Weight gain
03

In context

Premature Birth

2,553 studies on the registry are indexed under Premature Birth; 502 are open to participants now.

This study's planned enrollment of 80 is close to the median of 84 across 1,669 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University of Baghdad is the lead sponsor of 171 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 14 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm neonates born at 28-36 completed weeks of gestation. 2. Neonates admitted to the NICU and requiring incubator care. 3. Clinically stable preterm neonates.

Exclusion criteria

Exclusion Criteria:

  • Neonates requiring mechanical ventilation. 2. Neonates with congenital anomalies 3. Neonates with neurological or brain disorders 4. Neonates with severe sepsis
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Earmuff Intervention Group

    Preterm neonates receive earmuffs in addition to routine nursing care.

    Device: Neonatal Earmuffs

  • No intervention
    Control Group

    Preterm neonates receive routine nursing care alone, without the earmuff intervention.

Interventions

  • DeviceNeonatal Earmuffs

    External neonatal earmuffs will be used as a non-pharmacological intervention to reduce preterm neonates' exposure to environmental noise in the neonatal intensive care unit. The earmuffs will be applied according to the manufacturer's instructions and the study protocol. The intervention group will receive earmuffs in addition to routine neonatal care.

06

What researchers measure

Primary outcomes

  1. Sleep-Wake States in Preterm Neonates

    (ABSS) system.Sleep-wake states will be assessed using the Anderson Behavioral State Scale (ABSS). The scale ranges from 1 to 12. Scores from 1-4 indicate sleep states, 5-7 indicate awake states, and 8-12 indicate restless states. Higher scores indicate a worse outcome (more restless/fussy), while lower scores indicate a better outcome (deep sleep).

    Time frame: Daily for 5 days (each daily intervention session lasts 4 hours). For each session, measurements will be taken at: 2 minutes pre-intervention, during intervention, immediately post-intervention, and 1 hour post-intervention.

  2. Heart Rate in Preterm Neonates

    Heart rate will be measured in beats per minute (bpm) using a pulse oximeter.

    Time frame: Daily for 5 days (each daily intervention session lasts 4 hours). For each session, measurements will be taken at: 2 minutes pre-intervention, during intervention, immediately post-intervention, and 1 hour post-intervention.

  3. Respiratory Rate in Preterm Neonates

    Respiratory rate will be measured by direct observation for one minute (counting breaths per minute).

    Time frame: intervention.Daily for 5 days (each daily intervention session lasts 4 hours). For each session, measurements will be taken at: 2 minutes pre-intervention, during intervention, immediately post-intervention, and 1 hour post-intervention.

  4. Oxygen Saturation (SpO2) in Preterm Neonates

    Oxygen saturation will be measured as a percentage (%) using a pulse oximeter.

    Time frame: Daily for 5 days (each daily intervention session lasts 4 hours). For each session, measurements will be taken at: 2 minutes pre-intervention, during intervention, immediately post-intervention, and 1 hour post-intervention.

Secondary outcomes

  1. Weight Gain in Preterm Neonates

    Body weight will be measured in grams using a calibrated neonatal weighing scale, and weight change will be assessed.

    Time frame: Baseline (Day 1), Day 5 (end of intervention), and Day 10 (follow-up).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 744 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 3 months is below that.

Counting every sponsor, half of 762 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 12, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Feb 20, 2027
CompletionEst.
Jul 15, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934238
Responsible party
Marwa Yasir alwan (Principal Investigator, University of Baghdad) — Principal investigator
First posted
Nov 12, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Feb 20, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Marwa Y Alwan
Contact
marwa.yasir2504m@conursing.uobaghdad.edu.iq
+9647810597443

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion